Source: Fox News
Summary
A drug developed by Insilico Medicine for a lung disease may also slow biological aging, according to a small study. Patients taking rentosertib showed blood protein changes that made them appear three to four years younger. The results, published in Nature Biotechnology, were based on six aging tests and compared to data from 55,000 people. Researchers caution the findings are preliminary and do not prove the drug reverses aging or extends lifespan. The study involved 42 patients with idiopathic pulmonary fibrosis and showed manageable side effects.
Our Reading
This guidance has been heard before.
Drug studies often reveal unexpected benefits.
Biological age is a measure that shifts with new research.
Experts remain cautious about claims of aging reversal.
There is a familiar pattern in the way health breakthroughs are reported.
Author: Evan Null
Drug Development and Aging Research
The drug, rentosertib, was developed by Insilico Medicine in Massachusetts. It is being tested for idiopathic pulmonary fibrosis, a serious lung disease. Researchers found that patients taking the drug showed changes in blood proteins that made them appear biologically younger. This was an unexpected outcome of the study.
Biological Age and Protein Changes
Several tests estimated that patients were about three to four years younger biologically after treatment. In one case, the effect was up to six years. Six different aging tests showed similar results. The changes in blood proteins were compared to data from over 55,000 people in the UK Biobank.
Early Findings and Limitations
The study had a small sample size of 42 patients over 12 weeks. Researchers emphasized that the findings are preliminary and do not prove the drug reverses aging. The improvements in lung disease may have influenced the changes in blood proteins. More research is needed to determine the drug’s true effects.
Side Effects and Future Trials
Rentosertib had manageable side effects, including mild diarrhea, lower potassium levels, and temporary increases in liver enzymes. These effects returned to normal after stopping the drug. A larger phase 3 trial is now underway in China with over 300 patients. Future studies will include healthy older adults and populations without IPF.
Expert Caution and Future Goals
Researchers caution that the results do not support using the drug as an anti-aging treatment. They stress the need for larger and longer trials to confirm the findings. The goal is to determine if the drug can improve health and potentially extend lifespan. Experts remain skeptical about the claims of aging reversal.
